Table 3 Seroprotection and seroconversion rates for each vaccine strain

From: Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial

 

A/H1N1

A/H3N2

B/Victoria

B/Yamagata

Sinovac-QIV

Vaxigrip-TetraTM

p valuec

Sinovac-QIV

Vaxigrip-TetraTM

p valuec

Sinovac-QIV

Vaxigrip-TetraTM

p valuec

Sinovac-QIV

Vaxigrip-TetraTM

p valuec

N

132

131

 

132

131

 

132

131

 

132

131

 

SPRa Day 0% (95%CI)

15.2 (10.0-22.3)

13.7 (8.0-20.7)

0.863

43.9 (35.8-52.5)

38.9 (31.0-47.5)

0.453

54.5 (46.0- 62.8)

60.3 (51.7-68.3)

0.383

97.7 (93.5-99.4)

98.5 (94.6-99.7)

>0.9999

SPRa Day 28% (95%CI)

87.9 (81.2-92.4)

77.1 (69.2-83.5)

0.024

98.5 (94.6-99.7)

96.9 (92.4-98.8)

0.447

100 (97.2-100.0)

100 (97.2-100.0)

>0.9999

100 (97.2-100.0)

100 (97.2-100.0)

>0.9999

SCRb Day 28% (95%CI)

81.1 (73.5-86.8)

60.3 (51.7-68.3)

0.0002

98.5 (94.6-99.7)

69.5 (61.1-76.6)

<0.0001

81.1 (73.5-86.8)

77.1 (69.2-83.5)

0.452

55.3 (46.8-63.5)

45.8 (37.5-54.3)

0.14

  1. aAntibody titer \(\ge\)1:40.
  2. bSeroconversion rate is defined as either a pre-vaccination HAI antibody titer of <1:10 and a post-vaccination HI antibody titer of \(\ge\) 1:40, or a pre-vaccination HAI antibody titer of \(\ge\) 1:10 and a minimum 4-fold increase in post-vaccination HAI antibody at day 28.
  3. cFisher’s exact test.
  4. CI confidence Interval, SPR seroprotection rate, SCR seroconversion rate.
  5. All tests were two-sided, and p < 0.05 was considered statistically significant. 95% confidence intervals were calculated using the Wilson/Brown method.
Back to article page